Processing

Please wait...

Settings

Settings

Goto Application

1. WO1997028805 - THERAPEUTIC COMPOSITIONS CONTAINING A HEXAHYDRO-5-PYRIMIDINAMINE COMPOUND AND A MORPHOLINE-ETHER COMPOUND

Publication Number WO/1997/028805
Publication Date 14.08.1997
International Application No. PCT/US1997/002028
International Filing Date 07.02.1997
Chapter 2 Demand Filed 28.08.1997
IPC
A61K 31/535 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
CPC
A61K 31/535
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
Applicants
  • WARNER-LAMBERT COMPANY [US]/[US]
Inventors
  • CARLIN, Edward, James
  • TALWAR, Anil, Kumar
Agents
  • RYAN, M., Andrea
  • MANSMANN, Ivo
Priority Data
60/011,48309.02.1996US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) THERAPEUTIC COMPOSITIONS CONTAINING A HEXAHYDRO-5-PYRIMIDINAMINE COMPOUND AND A MORPHOLINE-ETHER COMPOUND
(FR) COMPOSITIONS THERAPEUTIQUES CONTENANT UN COMPOSE HEXAHYDRO-5-PYRIMIDINAMINE ET UN COMPOSE MORPHOLINE-ETHER
Abstract
(EN)
A therapeutic composition containing an antimicrobial hexahydro-5-pyrimidinamine compound and an anesthetic morpholine-ether compound in a pharmaceutically acceptable carrier is disclosed. The composition may be an oral topical composition or a non-oral topical composition. The preferred hexahydro-5-pyrimidinamine composition is hexetidine. The preferred morpholine-ether composition is pramoxine(4-[3-(4-butoryphenoxy)prozsyl]morpholine).
(FR)
L'invention concerne une composition thérapeutique contenant un composé antimicrobien hexahydro-5-pyrimidinamine et un composé anesthésique morpholine-éther dans un excipient pharmaceutiquement acceptable. Cette composition peut être une composition à action locale et à administration orale ou une composition à action locale à administration non orale. La composition préférée hexahydro-5-pyrimidinamine est hexétidine. La composition préférée morphoholine-éther est pramoxine(4-[3-(4-butoryphénoxy)prozsyl]morpholine).
Also published as
Latest bibliographic data on file with the International Bureau